Liraglutide works by mimicking the action of a hormone called GLP-1, which helps regulate blood sugar levels by stimulating insulin secretion, slowing down gastric emptying, and reducing appetite
The most common adverse events during the lead-in period were nausea, diarrhea, constipation and vomiting, and most events were mild or moderate
However, direct comparisons across these studies are limited by differences in design, patient selection, and follow-up duration
According to NICE guidance (NG28), GLP-1 receptor agonists like semaglutide are recommended as second- or third-line therapy, particularly for patients with a body mass index (BMI) 35 kg/m (or lower thresholds for people of Black African, African-Caribbean, South Asian, and Chinese family origin) or those for whom insulin therapy would pose significant occupational implications
Strive operates as a pharmacy rather than a clinic, which means the medical oversight model is different
Are natural supplements a safe alternative